
Life Sciences
Boston Biotech Rezera Says Its Pill Boosts Semaglutide's Anti-Inflammatory Effect
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.
Boston Business Watch reported on American Heart Association on October 7, 2026.
October 7, 2026
Separate RESOLVE-1 data are slated for the American Heart Association Scientific Sessions in Chicago, November 6-9, 2026.

Life Sciences
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.